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We  mutated  key  amino  acids  of  the  human  variant  of the  M1 muscarinic  receptor  that  target  ligand  bind-
ing,  receptor  activation,  and  receptor-G  protein  interaction.  We  compared  the  effects  of  these  mutations
on  the action  of  two  atypical  M1 functionally  preferring  agonists  (N-desmethylclozapine  and  xanomeline)
and  two  classical  non-selective  orthosteric  agonists  (carbachol  and  oxotremorine).  Mutations  of  D105
in the orthosteric  binding  site and  mutation  of  D99  located  out of  the  orthosteric  binding  site  decreased
afﬁnity  of  all  tested  agonists  that  was translated  as a decrease  in potency  in accumulation  of inositol
phosphates  and intracellular  calcium  mobilization.  Mutation  of  D105  decreased  the  potency  of  the  atyp-
ical agonist  xanomeline  more  than  that of  the  classical  agonists  carbachol  and  oxotremorine.  Mutation
of  the  residues  involved  in  receptor  activation  (D71)  and  coupling  to G-proteins  (R123)  completely  abol-
ished  the  functional  responses  to  both  classical  and atypical  agonists.  Our  data  show  that  both  classicalhemical compounds studied in this article:
arbachol (PubChem CID: 5831)
-desmethylclozapine (PubChem CID:
820)
xotremorine (PubChem CID: 4630)
anomeline (PubChem CID: 60809)
and  atypical  agonists  activate  hM1 receptors  by the same  molecular  switch  that  involves  D71  in the  sec-
ond  transmembrane  helix.  The  principal  difference  among  the studied  agonists  is  rather  in  the  way  they
interact  with  D105  in the  orthosteric  binding  site.  Furthermore,  our data  demonstrate  a  key role  of  D105
in  xanomeline  wash-resistant  binding  and  persistent  activation  of  hM1 by  wash-resistant  xanomeline.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Muscarinic acetylcholine receptors are abundantly expressed
n the central and peripheral nervous system and innervated tis-
ues. They serve a wide array of physiological roles ranging from
egetative functions up to cognition [1]. Damage of cerebral cholin-
rgic transmission either due to injury, neurodegeneration, toxins
r aging manifests itself as neurological or psychiatric diseases
ncluding Alzheimer’s disease [2,3] and schizophrenia [4]. Thus
uscarinic receptors represent an obvious target for pharmacolog-
cal interventions. Muscarinic ligands that are selective for certain
ubtypes of muscarinic receptors are needed for this purpose. How-
ver, all ﬁve muscarinic receptor subtypes share high sequence
omology, especially in the orthosteric binding site. Current
Abbreviations: CHO, Chinese hamster ovary; KHB, Krebs-HEPES buffer; NDMC,
-desmethylclozapine; NMS, N-methylscopolamine; TCA, trichloracetic acid.
∗ Corresponding author at: Institute of Physiology CAS, v.v.i., Vídenˇská 1083, 142
0  Prague, Czech Republic. Tel.: +420 2 4106 2620; fax: +420 2 4106 2488.
E-mail address: jakubik@biomed.cas.cz (J. Jakubík).
ttp://dx.doi.org/10.1016/j.phrs.2015.04.002
043-6618/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).crystallographic structures of M2 and M3 receptors [5,6] show that
homology in the secondary and tertiary structure extends even
beyond the orthosteric binding site. This high homology hindered
the discovery of ligands that bind selectively to speciﬁc receptor
subtypes. However, it has recently been discovered that certain
agonists that do not differentiate in their binding afﬁnity to various
muscarinic receptors display functional selectivity.
Xanomeline was among the ﬁrst agonists of this class
[7] followed by AC-42 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-
ﬂuoro-4H-benzo[1,4]oxazin-3-one) [8]. Subsequently, new M1
selective agonists based on TBPB ([1-(1–2-methylbenzyl)-1,4-
bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one]) [9] as well as
ones structurally related to AC-42 [10] and xanomeline [11,12]
were identiﬁed. Interestingly, all these M1 selective compounds
display deviations from competitive binding and can be considered
atypical agonists.
A particular feature of xanomeline binding to muscarinic recep-
tors is its resistance to extensive washing [7]. Wash-resistant
xanomeline affects binding of orthosteric ligands both compet-
itively and allosterically [13]. Xanomeline may  thus be labeled
as a dual-steric or bitopic agonist. Its functional but not binding
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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electivity makes it an attractive ligand for research of the
echanisms of receptor activation. During the past decade, the
echanisms of xanomeline binding have been partly identiﬁed
13] but the conundrum of xanomeline functional selectivity has
et to be satisfactorily untangled, especially in regard to its long-
erm antagonism of M5 receptors [14] and prolonged activation of
he remaining four muscarinic receptor subtypes that is preferen-
ial to M1 and M4 receptors [15]. Differential kinetics of receptor
ctivation [16,17], the ability of xanomeline to induce speciﬁc con-
ormations of muscarinic receptors [18,19] and multiple activation
witches in muscarinic receptors speciﬁc for allosteric ligands [20]
ay  explain its functional selectivity. Another interesting atyp-
cal M1 preferential muscarinic agonist is N-desmethylclozapine
NDMC), a pharmacologically active metabolite of clozapine, a
rug used in treatment of schizophrenia. Allosteric properties and
nique activation mode by NDMC have been described [21,22].
Besides its pure scientiﬁc interest, understanding the molecular
echanisms of functional agonist selectivity is key to knowledge-
ased development of functionally selective muscarinic agonists
ith potential therapeutic use. To address this question we
utated key amino acids of the human variant of the M1 muscarinic
eceptor that participate in ligand binding, receptor activation, and
eceptor-G protein interaction and compared how these mutations
ffect signal transduction by two atypical M1-preferring agonists
NDMC and xanomeline) and two classical non-selective orthos-
eric agonists (carbachol and oxotremorine).
. Materials and methods
.1. Receptor mutagenesis and generation of cell lines
New stable CHO cells lines expressing wild-type and mutant
1 receptors have been prepared. The mammalian expression vec-
or pcDNA3.1 (Invitrogen) containing the coding sequence of the
uman variant of M1 mAChR subtype was obtained from Missouri
&T cDNA Resource Center (Rolla, MO,  USA). This plasmid was  used
o generate hM1 mAChR sequences with the desired amino acid
ubstitution using Quick Change II Site-directed Mutagenesis Kit
Stratagene). Chinese hamster ovary (CHO-K1) cells were trans-
ected with either original hM1-pcDNA or mutated plasmid using
ipofectamine 2000 (Invitrogen). Subconﬂuent cells were washed
ith phosphate-buffered saline and Opti-MEM (Life Technologies)
ontaining Lipofectamine at ﬁnal concentration of 5 L/mL and
lasmid DNA at ﬁnal concentration of 1 g/mL was applied to the
ells for 6 h. After 48 h cells were diluted 10 times by subcultur-
ng and geneticin (Life Technologies) was added to the cultivation
edium to a ﬁnal concentration of 1000 ng/mL. Expression of
ew constructs was checked by reverse transcription quantitative
CR. Mediator RNA was isolated from CHO cell lines using TriPure
solation Reagent (Roche). Reverse transcription was done using M-
LV  Reverse Transcriptase (Promega), Oligo (dT) anchored primers
nd quantiﬁed using LightCycler® 480 SYBR Green I Master in
ightCycler® 480 Instrument II system (Roche) and analyzed by
ightCycler® 480 Software 1.5.0. Cell lines expressing wild-type
wt) or mutated M1 receptors with comparable receptor expres-
ion level were used for functional experiments. The numbering of
esidues of the hM1 receptor is used in this manuscript.
.2. Cell culture and membrane preparation
Chinese hamster ovary cells stably transfected with wild-type
wt) human M1 or mutated receptors were grown to conﬂuence
n 75 cm2 ﬂasks in Dulbecco’s modiﬁed Eagle’s medium supple-
ented with 10% fetal bovine serum. Two million cells were
ubcultured to 100-mm Petri dishes. Medium was supplementedal Research 97 (2015) 27–39
with 5 mM sodium butyrate for the last 24 h of cultivation to
increase receptor expression. Cells were washed with phosphate-
buffered saline and manually harvested on day 5 after subculture.
Cells were centrifuged for 3 min  at 250 × g. Pellet was suspended in
10 mL  of ice cold homogenization medium (100 mM NaCl, 20 mM
Na-HEPES, 10 mM EDTA, pH 7.4) and homogenized on ice by
two 30 s strokes using Polytron homogenizer (Ultra-Turrax; Janke
& Kunkel GmbH & Co. KG, IKA-Labortechnik, Staufen, Germany)
with a 30-s pause between strokes. Cell homogenates were cen-
trifuged for 5 min  at 1000 × g. The supernatant was  collected and
centrifuged for 30 min  at 30,000 × g. Pellets were suspended in
incubation medium (100 mM NaCl, 10 mM MgCl2, 20 mM Na-
HEPES, pH 7.4), left for 30 min  at 4 ◦C, and then centrifuged again
for 30 min  at 30,000 × g. Resulting membrane pellets were kept at
−80 ◦C until assayed.
2.3. Radioligand binding experiments
Membranes (10–30 g of membrane proteins per sample) were
incubated in 96-well plates for 3 h at 30 ◦C in 400 L of incuba-
tion medium. In saturation experiments of binding of [3H]NMS six
concentrations of the radioligand (ranging from 63 to 2000 pM)
were used. Alternatively, saturation binding was measured using
[3H]QNB in concentrations ranging from 12.5 to 400 pM at the M1
wt and ranging from 1.25 to 40 nM at the D105N mutant. Agonist
binding was  determined in competition experiments with 1 nM
[3H]NMS. Nonspeciﬁc binding was determined in the presence of
10 M atropine. In case of [3H]QNB saturation binding at D105N
mutant the concentration of atropine was increased to 40 M.  Incu-
bation was terminated by ﬁltration through Whatman GF/B glass
ﬁber ﬁlters (Whatman) using a Brandel harvestor (Brandel, USA).
Filters were dried in a microwave oven (3 min, 800 W)  then solid
scintillator meltilex A was melted on ﬁlters (105 ◦C, 60 s) using a
hot plate. The ﬁlters were cooled and counted in a Wallac Microbeta
scintillation counter (Wallac, Finland).
To determine xanomeline wash-resistant binding prior to incu-
bation with [3H]NMS membranes were either sham treated or
treated with xanomeline as follows. Membranes were resuspended
in incubation buffer (1 mg  of proteins per mL)  supplemented with
xanomeline in ﬁnal concentrations ranging from 100 nM to 1 mM
and incubated for 20 min  at 37 ◦C. Then membranes were washed
3-times in 10-fold volume of incubation buffer by recentrifugation
(30 min at 30,000 × g). Membranes were then resuspended in 10-
fold volume of incubation buffer and incubated for 1 h and again
washed 3-times by recentrifugation.
2.4. Accumulation of inositol phosphates (IPX)
Accumulation of inositol phosphates (IPX) was  assayed in
attached cells grown in 24-well plates. Cells were prelabeled over
night by 100 nM [3H]myo-inositol (ARC, USA) in 0.3 mL  of DMEM
at 37 ◦C. Cells were then washed with fresh medium and preincu-
bated in 0.4 mL  of DMEM containing 10 mM LiCl for 15 min at 37 ◦C.
The indicated concentrations of agonists were added and samples
were incubated for additional 20 min  in a ﬁnal incubation volume
of 0.5 mL. The reaction was stopped by adding 0.2 mL  of cold 20%
trichloroacetic acid (TCA). TCA precipitates were dissolved in 0.2 mL
of 1 M NaOH. Aliquots of TCA supernatants and lysates of sediments
were used for determination of IPX formation and incorporation of
radioactivity, respectively, by liquid scintillation counting.
Alternatively, accumulation of IPX was  determined after sepa-
ration on ion-exchange columns (Dowex 1X8-200, Sigma, USA). In
such case cells were harvested by mild trypsinization and resus-
penden in Krebs-HEPES buffer (KHB; ﬁnal concentrations in mM:
NaCl 138; KCl 4; CaCl2 1.3; MgCl2 1; NaH2PO4 1.2; Hepes 20;
glucose 10; pH adjusted to 7.4). First, cells were treated with
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anomeline or sham treated: Cells were incubated for 20 min  at
7 ◦C with xanomeline, washed 3 times with KHB, incubated in
xcess of KHB for 1 h at 37 ◦C and then washed 3 times with KHB.
fter treatment, cells were resuspended in KHB supplemented
ith 500 nM [3H]myo-inositol (ARC, USA) and incubated at 37 ◦C
or 1 h. Then cells were washed once with excess of KHB, resus-
ended in KHB containing 10 mM LiCl and incubated for 1 h at 37 ◦C.
ncubation was ended by addition of 0.5 mL  of stop solution (chlo-
oform:methanol:HCl; 2:1:0.1) and placed on ice for 20 min. An
liquot (0.65 mL)  of upper (aqueous) phase was  taken and loaded
nto ion-exchange columns. Columns were washed with 10 mL  of
eionized water and 20 mL  of 60 mM ammonium formate – 5 mM
odium borate solution. IPX were collectively eluted from columns
y 4 mL  of 1 M ammonium formate – 0.1 M formic acid buffer.
.5. Microﬂuorometry of intracellular calcium
Cells were washed twice with KHB and then pre-labeled with
 M Fura 2-AM in KHB enriched with 1 mM Pluronic® F-68 for
ne hour at 37 ◦C. After pre-labeling cells were washed twice with
HB, mounted to a superfusion chamber, placed on a stage of
lympus IX-90 inverted ﬂuorescent microscope, and continuously
uperfused at a ﬂow rate 0.5 mL/min. Images were recorded using
CD camera connected to a computer equipped with MetaFluor
.0 software (Visitron Systems GmBH, Germany) for image acqui-
ition and analysis. During the measurements images of the whole
isual ﬁeld containing about 40 cells were saved and analyzed off-
ine after the measurements. Two pairs of images per second were
ecorded. Only cells responding to the ﬁrst (control) carbachol or
xotremorine stimulation were selected (by exclusion of weakly
nd/or slow responding cells or cells with abnormal response; the
utliers in peak value, time to peak or fall time were identiﬁed by
nterquartile range (IQR) where data below Q1 − 1.5*IQR and above
3 + 1.5*IQR were considered outliers) for further analysis. Calcium
ignals of selected cells were averaged, normalized to basal calcium
evel and further analyzed by means of array oriented program
race [23].
Two general schemes of calcium measurements were employed.
n the ﬁrst scheme dependency of calcium response on the concen-
ration of agonist was measured. Cells expressing wild-type (wt)
nd mutant M1 receptors and naive CHO-K1 cells were exposed
or 10 s to increasing concentrations of tested agonists (carbachol,
xotremorine, NDMC or xanomeline) separated by 3–6 min  perfu-
ion with agonist free KHB medium. In the second scheme, effects
f prolonged exposure to xanomeline were tested. Initially, control
timulation with 10 M oxotremorine lasting 10 s was  performed.
fter 6 min  of perfusing with KHB cells were stimulated with 10 M
anomeline for 40 s. Calcium levels in the absence of xanomeline
ere measured for the subsequent 6 min.
.6. Data analysis
Data from experiments were processed in Libre Ofﬁce and then
nalyzed and plotted using program Grace [23]. Statistical analy-
is was performed using statistical package R [24]. For non-linear
egression analysis, the following equations were used:
[3H]NMS saturation binding
 = BMAX ∗
x
x + KD
(1)
here y is speciﬁc binding at free concentration x, BMAX is maxi-
um binding capacity, and K is equilibrium dissociation constant.D
Competition binding
 = 100 − (100 − flow) ∗
x
x + IC50 high
− flow ∗
x
x + IC50 low
(2)al Research 97 (2015) 27–39 29
where y is speciﬁc radioligand binding at concentration x of
competitor expressed as per cent of binding in the absence of com-
petitor, IC50 is concentration causing 50% inhibition of radioligand
binding, flow is fraction of low afﬁnity binding sites expressed in per
cents. Inhibition constant KI was calculated as:
KI =
IC50
1 + [D]/KD
(3)
where [D] is concentration of radioligand used and KD is its equi-
librium dissociation constant.
Concentration response curve
y = 1 + (EMAX − 1) ∗
xnH
xnH + EC50
(4)
where y is response normalized to basal at concentration x, EMAX is
maximal effect, EC50 is concentration causing half-maximal effect,
and nH is Hill coefﬁcient.
To compare efﬁcacies at receptors with different expression
level, the apparent afﬁnity constant KG of the G protein for the
agonist-receptor complex was calculated according to Lu and
Hulme [25] using the following equation:
KG =
EMAXFR
(1 − EMAX FR)/BMAX
(5)
where EMAX FR is maximal response calculated according to Eq.
(4) and expressed as a fraction of EMAX of carbachol (EMAX
agonist − 1)/(EMAX carbachol − 1) at M1 wt CHO cells with high expres-
sion and BMAX is maximum binding capacity of cell membranes
calculated according to Eq. (1).
2.7. Molecular modeling
2.7.1. Construction of homology models
Homology models of the human M1 receptor in active and
inactive states were constructed using YASARA software [26] as
described earlier [27]. For construction of the hM1 receptor in inac-
tive state structures, 3UON (M2 receptor with bound antagonist
quinuclidinyl bezilate (QNB)) and 4DAJ (M3 receptor with bound
antagonist tiotropium) were used as multiple templates. The result-
ing homology model of inactive hM1 receptor contains QNB bound
to the orthosteric binding site. For construction of hM1 receptor
in an active state, the structure 4MQS (M2 receptor in active state
stabilized by nanobody and bound agonist iperoxo) was used as a
single template. The resulting homology model of an active hM1
receptor contains iperoxo bound to the orthosteric binding site.
2.7.2. Agonist docking
Docking of agonists was done using Schrodinger Software Suit
(Schrödinger LLC, New York, NY). Homology model of the hM1
receptor in an active state was prepared for docking in Maestro
using Protein Preparation Wizard according to Sastry et al. [28]
guidelines. Structures of agonists were downloaded from PubChem
database (pubchem.ncbi.nlm.nih.gov) and prepared for docking in
Maestro using LigPrep. Individual agonists were docked to the
receptor using Induced Fit Docking procedure. Iperoxo was  set to
deﬁne the binding site. Size of binding site was  increased to con-
tain vestibule at the extracellular edge of transmembrane domain
to allow additional binding sites/modes to be identiﬁed. Initial Glide
docking step was  set to “Standard Precision” without explicit con-
strains. In Prime reﬁnement step amino acid residues within 5 A˚
form ligand were reﬁned in single pass. Residues N382 and D105
were excluded from reﬁnement. Glide re-docking step was set to
“Extra Precision”. For every ligand top 20 poses according to Glid-
eXP score were saved. Top poses were then reevaluated using Prime
MM-GB/SA.
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.7.3. Simulation of molecular dynamics
Prime MM-GB/SA top poses were taken for simulation of
olecular dynamics. Molecular dynamics was simulated using
esmond/GPU ver. 3.4. The simulated system consisted of
eceptor–ligand complex in 1-palmitoyl-2-oleoyl-sn-glycero-3-
hosphocholine (POPC) membrane set to receptor helices in water
nd 0.15 NaCl. The system was ﬁrst relaxed by standard Desmond
rotocol for membrane proteins and then 1.2 ns NPT (Noose–Hover
hain thermostat at 300 K, Martyna–Tobias–Klein barostat at
.01325 bar, isotropic coupling, Coulombic cutoff at 0.9 nm)  fol-
owed by 120 ns NVE molecular dynamics without restrains was
imulated. In Maestro the quality of molecular dynamics simula-
ion was assessed by Simulation Quality Analysis tools, analyzed
y Simulation Event Analysis tool and ligand–receptor interactions
ere identiﬁed using Simulation Interaction Diagram tool.
. Results
.1. Effects of mutations on muscarinic ligand binding
Amino acids in the orthosteric binding site (D105), vestibule
o binding pocket (D99), activation switch (D71) and receptor-G
rotein interface (D122 and R123) were mutated (Fig. 1). Binding
f the radiolabeled antagonist N-methylscopolamine ([3H]NMS) to
embranes from CHO cells expressing wild-type and mutant hM1
eceptor was measured directly in saturation binding experiments.
fﬁnities of [3H]NMS at individual receptors are summarized in
able 1. Mutations D71N, D99N and D105E slightly decreased the
fﬁnity for [3H]NMS whereas mutations D122N and R123N had no
ffect on [3H]NMS binding afﬁnity. Expression level in membranes
aried from 3.3 ± 0.4 to 15.8 ± 0.8 fmol of binding sites per g of
rotein at R123N and D105E, respectively (Table 2). No speciﬁc
inding of [3H]NMS was detected at the D105N mutant of hM1
ig. 1. Amino acids targeted by mutagenesis. Homology models of the hM1 receptor in a
onformation with bound iperoxo (right). Orientation: extracellular – top, TM VI and V
radient. Atoms: cyan – receptor carbon, blue – nitrogen, red – oxygen; yellow – hydrog
omains: blue – orthosteric binding site, green – transmission switch, yellow – tyrosine-t
nd  N382 in the orthosteric binding site. At inactive conformation D71 forms hydrogen b
orms  hydrogen bond with S112 in TM III. D122 and R123 are free in inactive conformatioal Research 97 (2015) 27–39
receptor at radioligand concentrations as high as 10-fold of its KD.
In sharp contrast, the radiolabeled antagonist quinuclidinyl benzi-
late ([3H]QNB) exhibited maximal binding of 5.8 ± 0.2 fmol binding
sites per g of protein in membranes of cells expressing the D105N
mutant, with pKD of 7.68 ± 0.03, while wild-type hM1 exhibited 7.9
± 0.3 fmol of [3H]QNB binding sites per g of protein, with pKD
of 9.82 ± 0.02 (means ± SEM, n = 3). According to quantitative RT-
PCR, mRNA level of CHO cell line stably transfected with the D105N
mutant was the same as mRNA levels of newly generated CHO cell
lines expressing mutants (D71N, D99N, D122N and R123N) and
wild-type human variant of M1 receptor.
Afﬁnities of agonists were measured indirectly in com-
petition binding experiments with 1 nM [3H]NMS. Carbachol,
oxotremorine, and xanomeline displayed two-site competition
binding while NDMC displayed only low afﬁnity binding at the
wild-type hM1 receptor (Fig. 2, Table 1). The proportion of low-
afﬁnity binding of oxotremorine and xanomeline was higher than
that of carbachol.
In general, mutations D71N, D99N, D105E, D122N and R123N
increased the proportion of low-afﬁnity sites with the exception of
xanomeline binding at D71N, D99N and D105E, and oxotremorine
at D99N and D122N. Mutant D122N bound xanomeline only with
low afﬁnity. All agonists bound to the R123N mutant with low
afﬁnity.
Mutation D71N increased the afﬁnity of low-afﬁnity binding of
carbachol, lowered afﬁnity of low-afﬁnity binding of oxotremorine
and had no effect on low-afﬁnity binding of xanomeline and
NMDC. In contrast, this mutation increased the afﬁnity of high-
afﬁnity binding of oxotremorine and xanomeline. Mutation D99N
decreased the afﬁnity of both high- and low-afﬁnity sites for
all tested agonists. Mutation D105E increased the afﬁnity of the
high-afﬁnity sites for xanomeline while high-afﬁnity binding of
carbachol and oxotremorine was  not detected at this mutant.
n inactive conformation with bound quinuclidinyl benzilate (left) and in an active
II – front. Backbone of the receptor is colored by position in red to white to blue
en bonds. D99 forms hydrogen bond with Q165 in o2 loop at both conformations.
oggle switch, red – ionic-lock switch. Both ligands form hydrogen bonds with D105
ond with N414 in TM VII that is part of tyrosine-toggle switch. Upon activation it
n and form hydrogen bonds with N60 in TM II upon receptor activation.
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Table 1
Afﬁnities of muscarinic ligands. Afﬁnities of muscarinic antagonist N-methylscopolamine (NMS) and agonists carbachol, N-desmethylclozapine (NDMC), oxotremorine and xanomline are expressed as negative logarithms of
equilibrium dissociation constant KD (NMS) or inhibition constant KI (agonists). KD was  obtained by ﬁtting Eq. (1) to the data from saturation experiments. KIs were computed from IC50s using Eq. (3). IC50s and flows were obtained
by  ﬁtting Eq. (2) to the data from competition experiments. Data are means ± S.E.M. from 3 to 8 independent experiments performed in quadruplicates.
NMS Carbachol NDMC Oxotremorine Xanomeline
pKD pKI high pKI low flow pKI low pKI high pKI low flow pKI high pKI low flow
wt  9.76 ± 0.03 6.45 ± 0.09 3.80 ± 0.04 70 ± 2 7.10 ± 0.02 8.96 ± 0.02 6.04 ± 0.03 83 ± 3a 10.12 ± 0.09 7.19 ± 0.04 82 ± 3a
D71N 9.29 ± 0.02* 6.49 ± 0.02 4.28 ± 0.04* 85 ± 3* 7.3 ± 0.1 9.7 ± 0.2* 5.50 ± 0.02* 91 ± 2* 10.59 ± 0.02* 7.32 ± 0.04 78 ± 3
D99N  9.41 ± 0.02* 5.7 ± 0.2* 3.31 ± 0.06* 85 ± 1* 6.86 ± 0.04* 8.56 ± 0.01* 5.51 ± 0.08* 86 ± 4 9.2 ± 0.2* 6.4 ± 0.1* 85 ± 4
D105N  n.b.
D105E 9.15 ± 0.05* n.c. 2.96 ± 0.03* 100* 6.59 ± 0.04* n.c. 6.01 ± 0.07 100* 11.36 ± 0.05* 6.50 ± 0.06* 70 ± 4a
D122N 9.65 ± 0.05 6.75 ± 0.01* 3.83 ± 0.04 82 ± 1* 6.94 ± 0.09 8.83 ± 0.01 5.83 ± 0.04* 89 ± 2 n.c. 6.85 ± 0.03* 100*
R123N 9.9 ± 0.1 n.c. 3.40 ± 0.1* 100* 7.17 ± 0.02 n.c. 5.80 ± 0.03* 100* n.c. 6.95 ± 0.01* 100*
n.b., no binding; n.c., not calculated; *, different from wt; a, flow different from flow of carbachol, P < 0.05, ANOVA and Dunnett’s post-test
Table  2
Parameters of accumulation inositol phospahtes stimulated by agonists. Half-efﬁcient concentration (EC50) and maximum of stimulation (EMAX)  were calculated by ﬁtting Eq. (4) to the data from measurements of inositol
phospahtes. Maximum biding capacities (BMAX) were calculated by ﬁtting Eq. (1) to the data from saturation binding experiments and are expressed in pmol per mg of protein. Efﬁcacies (KG) were calculated from EMAX and BMAX
values according to Eq. (5) and data from cell line with high expression of M1 wt  (BMAX = 11.3 ± 0.5; carbachol pEC50 = 5.90 ± 0.05; EMAX = 5.2 ± 0.3). Data are means ± S.E.M. from 3 to 8 independent experiments performed in
triplicates.
Carbachol NDMC Oxotremorine Xanomeline
BMAX pEC50 EMAX KG pEC50 EMAX KG pEC50 EMAX KG pEC50 EMAX KG
wt  7.6 ± 0.6 6.02 ± 0.04 3.5 ± 0.2 0.19 ± 0.01 6.5 ± 0.2 2.0 ± 0.3a 0.041 ± 0.006a 6.81 ± 0.08a 2.65 ± 0.03a 0.085 ± 0.001a 7.39 ± 0.09a 4.1 ± 0.2a 0.37 ± 0.02
D71N  6.9 ± 0.5 n.r. n.r. n.r. n.r.
D99N 10.6 ± 0.5 5.53 ± 0.08* 2.6 ± 0.2* 0.058 ± 0.004* 6.0 ± 0.1* 1.8 ± 0.2 0.022 ± 0.002* 6.22 ± 0.05* 2.98 ± 0.09* 0.084 ± 0.003 6.92 ± 0.08* 3.9 ± 0.2 0.21 ± 0.01*
D105N 5.8 ± 0.2 n.r. n.r. 5.8 ± 0.1* 2.4 ± 0.3* 0.086 ± 0.009 n.r.
D105E 15.8 ± 0.8 3.7 ± 0.1* 2.63 ± 0.03* 0.040 ± 0.01* 5.9 ± 0.2 1.14 ± 0.02* 0.0022 ± 0.0001* 5.73 ± 0.08* 1.35 ± 0.05* 0.0058 ± 0.0002* 5.6 ± 0.1* 1.8 ± 0.1* 0.015 ± 0.001*
D122N 4.1 ± 0.3 5.82 ± 0.03 2.5 ± 0.2* 0.14 ± 0.01 6.33 ± 0.08 1.63 ± 0.07* 0.043 ± 0.002 6.94 ± 0.07 2.7 ± 0.1 0.166 ± 0.006* 7.11 ± 0.09 3.3 ± 0.1* 0.30 ± 0.01
R123N  3.3 ± 0.2 n.r. n.r. n.r. n.r.
n.r., no response; *, different from wt; a, different from carbachol at wt,  P < 0.05 by ANOVA and Dunnett’s post-test.
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concentrations of agonists were needed at D105N to get the same2 A. Randáková et al. / Pharmac
utation D122N increased the afﬁnity of high-afﬁnity binding
f carbachol and decreased the afﬁnity of low-afﬁnity sites for
xotremorine and xanomeline. Mutation R123N decreased the
fﬁnity of low-afﬁnity sites for all agonists except NDMC.
.2. Effects of mutations on agonist-stimulated accumulation of
nositol phosphates
The rank order of potencies in stimulating accumulation
f inositol phosphates at the wild-type hM1 was: xanome-
ine > oxotremorine∼=NDMC > carbachol (Fig. 3, Table 2). To
ompare efﬁcacies at receptors with different expression level
he apparent afﬁnity constant KG of the G protein for the
gonist–receptor complex was calculated according to Lu and
ulme [25]. In concert with our previous ﬁndings, xanomeline
emonstrated twofold higher efﬁcacy than the classical full ago-
ist carbachol [15,16]. Efﬁcacies of NDMC and oxotremorine were
2% and 45% of carbachol efﬁcacy, respectively. None of the tested
gonists induced accumulation of inositol phosphates at the D71N
r R123N mutants. Mutation D99N decreased potency of all tested
gonists about three times. It also decreased the efﬁcacy of all tested
gonists except oxotremorine. Only oxotremorine stimulated accu-
ulation of inositol phosphates at the D105N mutant. Efﬁcacy of
xotremorine was the same but potency was 10-times lower than
t the wild-type. In contrast, all agonists stimulated accumula-
ion of inositol phosphates at the D105E mutant. Mutation D105E
ecreased potency of all agonists except NDMC. This mutation
aused about twofold decrease in efﬁcacy of NDMC and xanome-
ine, about ﬁvefold decrease in the efﬁcacy of carbachol and 15-fold
ecrease in the efﬁcacy of oxotremorine. Mutation D122N had no
ffect on the potency or efﬁcacy of agonists except an increase in
fﬁcacy of oxotremorine.
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High concentrations (30 M and higher) of NDMC decreased
accumulation of inositol phosphates in CHO cells expressing D71N,
D105N or R123N (mutants that do not show response at lower con-
centrations of NDMC) (Supplementary Fig. 1). However, the same
decrease in accumulation of inositol phosphates was detected in
non-transfected CHO-K1 cells. In contrast, high concentrations of
xanomeline (≥300 M)  increased accumulation of inositol phos-
phates in CHO cells expressing D71N, D105N or R123N mutants
while 1 mM xanomeline had no effect on accumulation of inos-
itol phosphates in non-transfected CHO-K1 cells (Supplementary
File 1).
3.3. Effects of mutations on agonist-evoked release of
intracellular calcium
Dependence of intracellular calcium mobilization on the con-
centration of the agonists carbachol, NDMC, oxotremorine and
xanomeline was  measured by ﬂuorescent microscopy of FURA-2
in perfused CHO cells expressing D105N, D105E or wild-type hM1
receptors (Fig. 4). As reported previously, the signal in our sys-
tem is very stable and independent from extracellular calcium [10].
At wild-type hM1 receptors the agonists carbachol, oxotremorine
and xanomeline produced transient increase in intracellular cal-
cium with a fast rise followed by a slow polyphasic decline (Fig. 4
left column). Time to peak ranged from 6.3 ± 0.3 s for carbachol
to 13.1 ± 0.5 s for xanomeline (mean ± S.E.M., n = 3). The fall time
ranged from 143 ± 6 s for oxotremorine to more than 360 s (length
of perfusion after stimulation) for xanomeline. In general, higher-12 -11 -10 -9 -8 -7 -6 -5 -4
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wt) and mutant M1 receptors in the presence of increasing concentrations of the
er left) and xanomeline (lower right) is plotted on ordinate as per cent of control
ments performed in quadruplicates. Binding parameters are summarized in Table 1.
response as at the wild-type hM1 receptor (Fig. 4 middle col-
umn). The rise of intracellular calcium was slower (time to peak
was 9.1 ± 0.3 s for carbachol and 16 ± 1 s for xanomeline) but the
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Fig. 3. Effects of agonists on accumulation of inositol phosphates. Accumulation of inositol phosphates in CHO cells expressing wild-type (wt) and mutant M1 receptors
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inding parameters are summarized in Table 2.
ollowing decline was faster (fall time was  127 ± 6 s for
xotremorine and 320 ± 15 s for xanomeline) than at wild-type
M1 receptors. In general, the D105E mutation had smaller impact
n potency of agonists than D105N. However, its impact on EMAX
alues was greater than at D105N. The rise times at D105E were
ven longer and fall times even shorter than at D105N (e.g. for
anomeline the time to peak was 23 ± 2 s and fall time was
50 ± 10 s).
Maximal changes in intracellular calcium concentration (EMAX)
rom Fig. 4 are plotted against agonist concentration in Fig. 5. The
xpression level of wild-type M1 receptor did not affect EMAX of
arbachol stimulation. Thus it is not possible to calculate KG val-
es. Xanomeline was the most potent in increasing intracellular
alcium level with pEC50 of 7.76 ± 0.04 followed by oxotremorine
7.43 ± 0.04) and carbachol (6.99 ± 0.03) (mean ± S.E.M., n = 3).
utation D105N decreased the potency of all tested agonists. The
trongest effect was on the potency of xanomeline, which showed
 decrease in potency of almost three thousand fold (to pEC50 of
.3 ± 0.04.) The decrease in potency of carbachol was  about one
undred times (to 4.89 ± 0.04) and was less than 10 times for
xotremorine (to 6.50 ± 0.03). Mutation D105N slightly decreased
aximal response values of carbachol and xanomeline. The max-
mal response of oxotremorine remained unchanged. In contrast,
utation D105E decreased the maximal response of carbachol,
anomeline and oxotremorine to 58 ± 3, 36 ± 2 and 24 ± 1% of
he value at the wild-type receptor, respectively. In comparison
o D105N, at D105E mutant decrease in potency was  the same
or oxotremorine (about 10-fold) but smaller for carbachol and
anomeline (less than 30-fold).ylclozapine (upper right), oxotremorine (lower left) and xanomeline (lower right) is
a are means ± S.E.M. from 3 to 7 independent experiments performed in triplicates.
NDMC increased intracellular calcium levels in non-transfected
CHO-K1 cells at concentrations as low as 10 nM and higher (Supple-
mentary File 1) rendering measurements of NDMC action at cells
expressing hM1 receptor variants unfeasible. Thus, this assay was
unsuitable for analysis of the effects of D105N mutation on the
action of NDMC. None of the tested agonists changed calcium level
at the D71N and R123N mutants (data not shown).
3.4. Effects of mutations on extended exposure to xanomeline
In these measurements the effects of mutations D99N, D105N,
D105E and D122N on calcium responses evoked by prolonged
exposure to xanomeline were estimated. After 10-s initial period,
control stimulation with 10 M oxotremorine was  performed for
10 s. Control stimulation was followed by 6-min washing with
buffer, 40-s stimulation with 10 M xanomeline and another 6-
min  washing with buffer (Fig. 7). In comparison to the wild-type
receptor, mutations D99N and D122N had no effect and muta-
tions D105N and D105E decreased the maximal calcium response
induced by control oxotremorine stimulation. Exposure of cells
expressing the wild-type receptor to 10 M xanomeline for 40 s
led to transient increase (peak of 1.93 ± 0.02; mean ± S.E.M., n = 3)
in intracellular calcium followed by a plateau (1.31 ± 0.02 of basal).
All tested mutations decreased both peak and plateau values com-
pared to wild-type hM1 receptors (P < 0.05, paired t-test). The effect
of D99N mutation was the weakest (1.88 ± 0.02 and 1.26 ± 0.02 for
peak and plateau values, respectively) and that of D105N mutation
was the strongest (1.12 ± 0.02 and 1.03 ± 0.02, respectively). The
34 A. Randáková et al. / Pharmacological Research 97 (2015) 27–39
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2
Em
is
si
on
 ra
tio
 [3
40
 nm
 / 3
80
 nm
] wt carbachol
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2 D105N carbachol
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
Em
is
si
on
 ra
tio
 [3
40
 nm
 / 3
80
 nm
] wt oxotremorine
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8 D105N oxotremorine
-6.5
-6
-5.5
-5
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2
Em
is
si
on
 ra
tio
 [3
40
 nm
 / 3
80
 nm
] wt xanomeline
-9
-8.5
-8
-7.5
-7
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2 D105N xanomeline
-4.5
-4
-3.5
-3
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2 D105E carbachol
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8 D105E oxotremorine
0 100 200 300 400
Time [s]
0.8
1
1.2
1.4
1.6
1.8
2
2.2 D105E xanomeline
log c
Fig. 4. Time-courses of changes in intracellular calcium level upon exposure of cells to agonists. Time-courses of intracellular calcium of the CHO cells expressing wild-type
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lateau at D105N as well as D105E was signiﬁcantly higher than
asal (P < 0.05, one-tail t-test).
.5. Effects of mutations on xanomeline wash-resistant binding
nd associated persistent receptor activationThe apparent afﬁnity of xanomeline wash-resistant binding at
ild-type hM1 receptors was 260 M.  Mutations, except D99N
nd D105E, had no effect on the apparent afﬁnity of xanomeline the agonists carbachol (top), oxotremorine (middle) and xanomeline (bottom) at
 expressed as 340 nm to 380 nm emission ratio normalized to basal level. Abscissa,
nﬁrmed by 2 additional independent experiments.
wash-resistant binding. Mutation D99N caused about threefold and
mutation D105E more than 10-fold decrease in afﬁnity (Table 3).
Wash-resistant xanomeline stimulated accumulation of inosi-
tol phosphates with half-maximal response at 1 M.  Mutations
D71N, D105N and R123N abolished accumulation of inositol phos-
phates induced by wash-resistant xanomeline. Mutations D99N,
D105E and D122N had no effect on the potency of wash-resistant
xanomeline. Only mutation D105E caused a twofold decrease in
efﬁcacy.
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Fig. 5. Concentration dependence of the maximal response of intracellular calcium
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Fig. 6. Time-courses of changes in intracellular calcium level upon prolonged expo-
sure  of the cells to xanomeline. Time-courses of intracellular calcium level in CHO
cells expressing wild-type (black), or D99N (red), D105N (green), D105E (yellow)
and D122N (blue) mutant M1 receptors are shown. After control 10-s stimulation
with 1 M oxotremorine (oxo) cells were perfused with agonist-free KHB. At the
beginning of the seventh min  cells were exposed for 40-s to 10 M xanomeline and
then perfused with agonist-free KHB till the end of measurement. Intracellular cal-
cium level (ordinate) is expressed as 340 nm to 380 nm emission ratio normalized
to  basal level. Traces are averages from 8 to 12 cells from representative experimentachol (black), oxotremorine (red) and xanomeline (blue) are plotted against used
oncentration of agonists (abscissa). Data are means ± S.E.M. from 3 independent
xperiments.
.6. Molecular modeling of agonist binding
The agonists carbachol, NDMC, oxotremorine and xanomeline
ere docked to the homology model of the hM1 receptor in an
ctive state. Generated poses were re-scored using Prime MM-
B/SA. Top poses of all tested agonists interact with key amino
cids (D105 in TM III and N382 in TM VI) of the orthosteric binding
ite (Fig. 6). Molecular dynamics (MD) of top poses was simulated.
gonist–receptor interactions were inferred from MD  trajectories
sing Ligand Interaction Diagram in Maestro (Fig. 8). The principal
ifference found by analysis of ligand receptor interactions over
D trajectory is in interaction of agonists with key amino acids
t the orthosteric binding site, namely D105 and N382. The ioniz-
ble nitrogen of carbachol, NDMC and xanomeline binds strongly
o D105 via ionic bond. Further, the ionizable nitrogen forms
ydrogen bonds and water bridges with D105 (NDMC, xanome-
ine) or Y106 (carbachol). In contrast, oxotremorine binds only
eakly to D105 via water bridges. The classical agonists carba-
hol and oxotremorine form hydrogen bonds and water bridges
ith N382. As for atypical agonists hydrogen bonding to N382 is
uch less abundant (NDMC) or negligible (xanomeline). Another
able 3
arameters of wash-resistant xanomeline binding and stimulation of accumulation
f inositol phosphates. Apparent afﬁnity of xanomeline wash-resistant binding is
xpressed as negative logarithms of inhibition constant KI that was computed from
C50 using Eq. (3). IC50s and flows were obtained by ﬁtting Eq. (2) to the data from
ompetition experiments. Data ﬁt to single population of low afﬁnity sites. Half
fﬁcient concentration (EC50) and maximum of stimulation (EMAX) were calculated
y  ﬁtting Eq. (4) to the data from measurements of inositol phosphates. Efﬁcacy
KG) was calculated from EMAX and BMAX values according to Eq. (5) and data from
ell line with high expression of M1 wt (BMAX = 11.3 ± 0.5; wash-resistant xanome-
ine pEC50 = 6.2 ± 0.1; EMAX = 5.5 ± 0.2). Data are means ± S.E.M. from 3 independent
xperiments performed in quadruplicates.
Wash-resistant xanomeline
pKI pEC50 EMAX KG
wt  4.34 ± 0.06 6.0 ± 0.1 3.8 ± 0.3 0.22 ± 0.02
D71N 4.37 ± 0.08 n.r.
D99N 3.81 ± 0.05* 6.08 ± 0.06 4.3 ± 0.3 0.26 ± 0.02
D105E 3.20 ± 0.1* 6.0 ± 0.1 1.6 ± 0.1 0.010 ± 0.001*
D122N 4.17 ± 0.06 5.9 ± 0.1 2.9 ± 0.1 0.18 ± 0.01
R123N 4.39 ± 0.06 n.r.
.r., no response; *, different from wt; P < 0.05 by ANOVA and Dunnett’s post-test.conﬁrmed by two  additional independent experiments. Abscissa, time in seconds.
marked difference is in the interaction with Y381. While carbachol,
oxotremorine and xanomeline exhibit hydrophobic interactions
with Y381, the nitrogen in atomic position 4 of NDMC forms a
hydrogen bond with this amino acid. Importantly, xanomeline
binds to D105 strongly via ionic or hydrogen bonds 100% of the
time during MD simulation while carbachol binds to D105 via ionic
bond in less than 20% of the time and oxotremorine binds to D105
only weakly via water bridges. Changes in binding energy due
to repulsion between N105 in the reverse-charge mutant D105N
and agonist nitrogen is much greater than needed for rearrange-
ment of water bridges. Thus, the decrease in afﬁnity and potency
is greatest for xanomeline, medium for carbachol and smallest for
oxotremorine.
4. Discussion
The main ﬁnding of this work is that classical as well as atypical
agonists activate M1 muscarinic receptors by the same mechanism
involving the D71 activation switch. Further crucial role of the
orthosteric binding site in activation by atypical agonists was
demonstrated. This is in contrast to studies that suggested that
N-desmethylclozapine (NDMC) induces a speciﬁc mode of M1
receptor activation [22] and preferentially activates this recep-
tor by interacting with a site that does not fully overlap with
the acetylcholine orthosteric site [21], and other studies that
suggested the existence of multiple activation switches speciﬁc
for allosteric ligands at muscarinic receptors [20]. Several lines
of evidence suggest that atypical agonists may induce different
receptor conformations and possibly utilize different activation
mechanisms at the molecular level. These include differential
kinetics of receptor activation by xanomeline [16] (and other
agonists [17]) and the existence of agonist-speciﬁc conformations
of muscarinic receptors [18,19]. To test whether there are principal
differences in the action of atypical and classical agonists, we
mutated key amino acids of the human variant of the M1 receptor
targeting ligand binding, receptor activation, and receptor-G pro-
tein interaction (Fig. 1) and compared effects of these mutations
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Fig. 7. Top poses of agonists. Top docking poses of carbachol (upper left), NDMC (upper right), oxotremorine (lower left) and xanomeline (lower right) according Prime
MM-GB/SA are shown from the extracellular view. Orientation, TM III up and TM VI down. Helices TM II to TM VII are shown in purple. Ligands and displayed amino acids
(D105, Y106, S109, W378, Y381, N382 and Y404) are colored according elements: cyan – carbon, white – hydrogen, blue – nitrogen, red – oxygen, yellow – sulfur. Yellow
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n the action of two atypical M1 preferring agonists (NDMC and
anomeline) and two classical non-selective orthosteric agonists
the full agonist carbachol and the partial agonist oxotremorine).
Aspartate in the middle of TM III (D3.32, numbering accord-
ng Ballesteros and Weinstein [29]) is conserved among aminergic
PCRs (subclass A17 through A19) and is essential for ligand bind-
ng. Opsin receptors (subclass A16) have glutamate in this position
hat interacts with opsins. On the other hand, chemokine recep-
ors have basic amino acids in this position. D3.32 of muscarinic
eceptors (D105 in the hM1 sequence; Fig. 1) has been identi-
ed to be essential for binding of classical muscarinic agonists
nd antagonists and it has been proven that it interacts with the
ositively charged nitrogen moiety of muscarinic ligands [30,31].
utation of D105 to asparagine completely ablated binding of
he tritiated antagonist N-methylscopolamine ([3H]NMS) (Table 1)
nd decreased the afﬁnity of quinuclidinyl benzilate more than
00-times. Deteriorating effects of D105N and D105E mutations
n binding were projected to functional assays (Fig. 3, Table 2).
urprisingly, the mutations D105N and D105E in the orthosteric
inding site decreased potency of xanomeline (an atypical agonist
ith allosteric properties) more than the potency of carbachol and
xotremorine (classical agonists believed to bind primarily to the
rthosteric binding site) (Figs. 4 and 5).Effects of mutations of D105 on ligand binding may  be explained
by molecular modeling that shows that while all tested agonists
bind to the orthosteric binding site (Fig. 7), agonists differ in the
way they interact with individual amino acids within this site, espe-
cially D105 (Fig. 8). This is in accordance with current ﬁndings [32].
Speciﬁcally, xanomeline binds to D105 strongly via ionic or hydro-
gen bonds 100% of the time during MD simulation. Carbachol binds
to D105 via ionic bond in less than 20% of the time of MD simula-
tion. Oxotremorine binds to D105 only weakly via water bridges.
Change in binding energy due to repulsion between N105 in the
reverse-charge mutant D105N and agonist’s charged quaternary
nitrogen is much greater than the change in binding energy due
to rearrangement of water bridges. Thus, the decrease in afﬁnity
and potency is greatest for xanomeline, medium for carbachol and
smallest for oxotremorine. Analogously, afﬁnity of antagonist con-
taining charged quaternary nitrogen (NMS) is affected more than
afﬁnity of antagonist containing ternary nitrogen (QNB). Conserved
mutant D105E only changes geometry of the orthosteric binding
site. Thus its effects on agonist afﬁnity and potency are smaller in
comparison to the reverse-charge mutant D105N. Thanks to ﬂexi-
bility of oxotremorine binding to E105 via water bridges, afﬁnity
of this agonist is not affected by the D105E mutation (Table 1).
However, proper conformational change upon agonist binding is a
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Fig. 8. Interaction of agonists with receptor. Histograms of carbachol (upper left), NDMC (upper right), oxotremorine (lower left) and xanomeline (lower right) interactions
with  the receptor were calculated from MD trajectories using Ligand Interaction Diagram in Maestro. Ligand-receptor interactions are categorized into four types: Hydrogen
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rerequisite for receptor activation and thus oxotremorine potency
s severely affected by this mutation (Table 2).
Aspartate at the junction of the third transmembrane helix (TM
II) and the second extracellular (o2) loop D3.26 (D99 in the hM1
equence; Fig. 1) is not conserved among GPCRs. Adrenergic recep-
ors have glutamate in this position and mutation of this glutamate
o alanine had no effects on afﬁnity of agonists and antagonists
33]. However it has been shown that mutation of D99 at M1
uscarinic receptors decreases afﬁnity and accelerates kinetics of
inding of muscarinic ligands [34,35]. A tandem two-site binding
odel for muscarinic ligands was proposed to explain the role
f this aspartate [36]. The model was conﬁrmed by simulation
f molecular dynamics of ligand binding to M2 and M3 receptors
hat showed metastable binding state in the extracellular domain
vestibule to the orthosteric site) [6]. Mutation of this aspartate
D99N) decreased the afﬁnity of the antagonist NMS  as well as
ll tested agonists (Table 1). The decrease in agonist afﬁnity was
ranslated as decreased potency of all agonists in functional assays
Table 2). Taken together both D105 within the orthosteric binding
ite as well as D99 out of the orthosteric binding site participate in
inding of all tested agonists.
Network transducing conformational change upon ligand
inding that is common among aminergic GPCRs includes a “trans-
ission switch” (WXP motif in TM VI), a “tyrosine-toggle switch”
NPXXY motif in TM VII) and “ionic-lock switch” (DRY motif in
M III interacting with glutamate 6.30) [37,38] (Fig. 1). The aspar-
ate D2.50 in the middle of TM II is conserved throughout GPCRs
nd its reverse-charge mutation to asparagine ablates functional
esponse of many GPCRs including serotonin, adrenergic, cannabi-
oid, thyrotropin-releasing hormone, etc. (GPCR database; www.
pcr.org/7tm). Speciﬁcally, D2.50 of muscarinic receptors (D71 in
he hM1 sequence) interacts with N7.49 (N414 in the hM1 sequence)
n tyrosine-toggle switch and transfers the conformational change
pon agonist binding to the receptor-G protein interface [38,39].
dditional mechanisms of receptor activation were identiﬁed
mong Class A of GPCRs [40–43] including muscarinic receptors charts are normalized over the course of the trajectory. Values over 1.0 are possible
ithin one time-frame.
[20]. Interestingly, irreversible agonist of 2-adrenergic receptors
activates them through an activation switch that contains I3.40, P5.50
and F6.44 [44] and is parallel to the common network of activation
switches. However, mutation D71N completely abolished the abil-
ity of all tested agonists to activate the receptor (Table 2; Fig. 3)
and renders the possibility that tested atypical agonists utilize
activation mechanisms that parallel common activation network
unlikely. Thus, atypical agonists activate the hM1 receptor by the
same molecular switch as classical agonists.
Arginine R3.50 at the intracellular end of TM III is conserved
within all GPCRs. It has been shown to interact directly with the
-subunit of G-proteins [45]. Although in the majority of cases,
mutation of R3.50 leads to complete loss of functional response
to agonists (GPCR database; www.gpcr.org/7tm/mutant), non-
conservative mutations of this amino acid do not abolish signaling
via G-proteins in some cases [46,47]. In accordance with previous
ﬁndings [34], mutation of R3.50 (R123N) completely abolished the
ability of carbachol to activate the receptor as it failed to stimu-
late accumulation of inositol phosphates (Table 2) and release of
calcium from intracellular stores. This mutation also abolished the
functional response to tested atypical agonists. Unlike the D71N
mutation, R123N decreased the afﬁnity of agonists at the low-
afﬁnity binding site (Table 1, Fig. 2 left triangles), demonstrating
that inactive (D71N) and un-coupled (R123N) represent different
states of the receptor [48].
The role of the aspartate/glutamate in the conserved E/DRY
motif (position 3.49) is to stabilize the interaction of TM III and
TM VI of the inactive receptor and thus stabilizes the inactive
conformation of the receptor [49]. Similar to adrenergic [50] and 5-
hydroxytryptamine [51] receptors, mutation of D3.49 to asparagine
(D122N) in muscarinic receptors results in an increase in receptor
constitutive activity [18] by destabilization of the inactive confor-
mation. The most profound effect of D122N was  an increase in the
proportion of low-afﬁnity binding sites (Table 1, Fig. 2 squares). The
increase in low-afﬁnity sites is probably a consequence of increased
basal activity of the receptor.
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Part of xanomeline binding is resistant to washing and leads
o long-term receptor activation [7]. Exposure of the wild-type
M1 to a high concentration of xanomeline led to sustained acti-
ation (Fig. 6, black trace). The ratio between peak and plateau
evels of intracellular calcium at D105N and D105E is similar to
hat at the wild-type receptor, indicating that xanomeline bind-
ng to the orthosteric binding site is a prerequisite for formation of
anomeline wash-resistant binding and activation. The apparent
quilibrium dissociation constant of xanomeline wash-resistant
inding is the same for wild-type and mutants with the exception of
 decrease at D105E (Table 3). Also only D105E among functional
utants decreased the efﬁcacy of wash-resistant xanomeline to
timulate accumulation of inositol phosphates. These data suggest
he importance of D105 in the orthosteric binding site for long-
erm activation by wash-resistant xanomeline. This is in concert
ith the ﬁnding that blocking of the orthosteric site by the antago-
ist NMS  transiently diminishes activation of muscarinic receptors
y wash-resistant xanomeline [15].
In summary, our data show that the principal difference
etween classical and atypical agonists is in the way  they interact
ith the orthosteric binding site. However, the atypical agonists
DMC and xanomeline activate M1 muscarinic receptor via the
ame molecular switch as the classical agonists carbachol and
xotremorine that involves D71 in TM II. Data also demonstrate
 key role of the orthosteric binding site in long-term receptor
ctivation by wash-resistant xanomeline.
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